4//SEC Filing
Mann Brenda 4
Accession 0001104659-21-011852
CIK 0001372514other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 9:53 PM ET
Size
8.0 KB
Accession
0001104659-21-011852
Insider Transaction Report
Form 4
Mann Brenda
VP of Research & Development
Transactions
- Tax Payment
Common Stock
2021-02-02$6.34/sh−988$6,264→ 16,268 total - Award
Stock Option (right to buy)
2021-02-01+10,000→ 10,000 totalExercise: $6.46Exp: 2031-02-01→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]Sale of shares to cover taxes due on restricted stock that vested on 02/01/2021.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.32 to $6.34, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.
Documents
Issuer
EYEGATE PHARMACEUTICALS INC
CIK 0001372514
Entity typeother
Related Parties
1- filerCIK 0001668858
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 9:53 PM ET
- Size
- 8.0 KB